Live Breaking News & Updates on Covaxin vaccine

Stay informed with the latest breaking news from Covaxin vaccine on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Covaxin vaccine and stay connected to the pulse of your community

'Very good move': Poonawalla on longer gap between Covishield jabs

'Very good move': Poonawalla on longer gap between Covishield jabs
Health ministry has accepted recommendations of Covid-19 working group of National Technical Advisory Group on Immunisation and National Expert Group on Vaccine Administration for Covid-19 to administer second jab after 12-16 weeks after the first one
BusinessToday.In | May 14, 2021 | Updated 10:38 IST
Serum Institute of India chief executive Adar Poonawalla
Serum Institute of India chief executive Adar Poonawalla has hailed the government decision to increase the gap between two Covishield doses to 12-16 weeks from the current gap of 6-8 weeks.
The health ministry on Thursday accepted the recommendations of the Covid working group of the National Technical Advisory Group on Immunisation (NTAGI) and the National Expert Group on Vaccine Administration for Covid-19 (NEGVAC) to administer the second jab after 12-16 weeks of the first one.

India , Adar-poonawalla , Rajesh-bhushan , National-technical-advisory-group-on-immunisation , Serum-institute-of-india , Serum-institute , National-technical-advisory-group , National-expert-group , Vaccine-administration , Bharat-biotech , Covid-19-vaccination-in-india , Vaccination-for-covid-19

Centre asks Pfizer, Moderna and J&J to supply COVID-19 vaccines to India

Centre asks Pfizer, Moderna and J&J to supply COVID-19 vaccines to India
Dr VK Paul, head of India's Covid-19 Task Force said, "We have contacted manufacturers and sought information on the availability of vaccine for August-December..."
BusinessToday.In | May 14, 2021 | Updated 12:33 IST
COVID-19 in India: Centre reaches out to vaccine makers
The Centre has said that it is in talks with three global manufacturers including Pfizer, Moderna and Johnson & Johnson to supply coronavirus vaccines in the country. However, the manufacturers have said that they would be able to open discussions only in Q3 2021. The government said that nevertheless, over 2 billion doses of COVID-19 vaccines would be available in India between August and December this year as per estimates given by the manufacturers.

India , Pfizer , Johnson , Covid-19-vaccination-in-india , Vaccination-for-covid-19 , Covid-19-vaccination , Covid-19-vaccination-programme , Covid-19-vaccine , Vaccination-in-india , Covid-vaccination , Covid-vaccine

Extension of gap between Covishield doses 'reasonable approach', says Dr Fauci

Extension of gap between Covishield doses 'reasonable approach', says Dr Fauci
"When you are in a very difficult situation, the way you are in India, you have to try and figure out ways to get as many people vaccinated as quickly as you can," said Dr Fauci
BusinessToday.In | May 14, 2021 | Updated 18:09 IST
Amid the furore over the extension of the gap between two doses of Covishield, White House chief medical adviser Dr Anthony Fauci said that it is a 'reasonable approach'. He said that if one is in a situation that India finds itself in currently, then one would have to try and figure out other ways to get as many as possible vaccinated.

India , White-house , District-of-columbia , United-states , Anthony-fauci , Covid-19-vaccination-in-india , Vaccination-for-covid-19 , Covid-19-vaccination , Covid-19-vaccination-programme , Covid-19-vaccine , Vaccination-in-india , Covid-vaccination

Covid-19: DCGI approves phase 2, 3 clinical trials of Covaxin on children aged 2 to 18 years | India News

Kolkata: A medic shows a vial containing doses of Covaxin during a Covid-19 vaccination drive at a government hospital, in Kolkata. (PTI)
NEW DELHI: The Drugs Controller General of India (DCGI) approved phase 2 and 3 clinical trial of Bharat Biotech's Covaxin vaccine in the age group of 2 to 18 years, the ministry of health and family welfare informed on Thursday.
"The National Regulator of the country, the Drugs Controller General of India (DCGI), after careful examination, has accepted the recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II/III clinical trial of Covaxin (Covid vaccine) in the age group 2 to 18 years, to its manufacturer Bharat Biotech Ltd on May 12, 2021," the ministry said.

India , Bharat , Covaxin-covid , National-regulator , National-institute-of-virology , Indian-council-of-medical-research , Expert-committee , Bharat-biotech-ltd-on , Drugs-controller-general , Bharat-biotech , Subject-expert-committee , Bharat-biotech-ltd

Increase gap between Covishield doses to 12-16 weeks, suggests top govt panel

Increase gap between Covishield doses to 12-16 weeks, suggests top govt panel
Additionally, the panel suggested that pregnant women should be offered the choice of vaccine and lactating women can be inoculated any time after delivery
BusinessToday.In | May 13, 2021 | Updated 12:42 IST
National Technical Advisory Group on Immunisation (NTAGI) has called for an increase in the gap between two doses of Covishield
A central government panel has suggested increasing the gap between two doses of Covishield. The National Technical Advisory Group on Immunisation (NTAGI) has called for an increase in the gap between two doses of Serum Institute's vaccine to 12-16 weeks from the current four-eight weeks. The panel did not suggest any change in the dosage interval for COVAXIN.

Jairam-ramesh , Twitter , Serum-institute , National-expert-group-on-vaccine-administration , National-technical-advisory-group-on-immunisation , National-technical-advisory-group , National-expert-group , Vaccine-administration , Covid-19-vaccination-in-india , Vaccination-for-covid-19 , Covid-19-vaccination , Covid-19-vaccination-programme

Bharat Biotech agrees to open Covaxin manufacturing to others

Bharat Biotech agrees to open Covaxin manufacturing to others
Bharat Biotech has been producing Covaxin at its Biosafety Level-3 (BSL-3) facilities in Hyderabad and Bengaluru, where Production capacity had been enhanced in a step-wise manner
BusinessToday.In | May 13, 2021 | Updated 19:04 IST
Bharat Biotech has agreed to allow other companies to manufacture its coronavirus vaccine Covaxin, informed NITI Aayog Member (Health) Dr VK Paul. Addressing a press conference on the status of COVID-19 situation in the country on Thursday, Paul invited companies interested in joining the initiative to expand the production of Covaxin.
"People have asked that Covaxin be given to other companies for manufacturing. I am happy to say that Covaxin manufacturing company [Bharat Biotech] has welcomed this when we discussed it with them. Under this vaccine live virus is inactivated and this is done only in BSL3 labs," Paul said.

India , Hyderabad , Andhra-pradesh , Bengaluru , Karnataka , Pune , Maharashtra , Bharat , Union-health-ministry , Bharat-biotech-ltd , Serum-institute-of-india

'You don't have enough vaccine': Delhi HC slams Centre over dialer tune urging people to vaccinate

'You don't have enough vaccine': Delhi HC slams Centre over dialer tune urging people to vaccinate
"You are not vaccinating people, but you still say that vaccination lagavaiye (get vaccinated). Kaun lagayega vaccine (who will give vaccine), when there is no vaccination," said the Delhi High Court
BusinessToday.In | May 13, 2021 | Updated 19:37 IST
Delhi HC slams Centre over COVID-19 vaccine dialer tune
Delhi High Court criticised the Centre over the dialer tune urging people to get vaccinated when there is a shortage of vaccine doses. The court said that the 'irritating' message was played for 'don't know how long' asking people to get vaccinated when there is not enough vaccine.

Delhi , India , Vipin-sanghi , Amitabh-bachchan , Rekha-palli , Delhi-high-court , Justices-vipin-sanghi , Covid-19-vaccination-in-india , Vaccination-for-covid-19 , Covid-19-vaccination , Covid-19-vaccination-programme

India's new COVID-19 cases have peaked, states Cambridge tracker

According to a new tracker developed by researchers at the Cambridge Judge Business School and the National Institute of Economic and Social Research, new cases have peaked in the country

India , Tripura , Cambridge , Cambridgeshire , United-kingdom , Himachal-pradesh , Tamil-nadu , Narendra-modi , Business-school , National-institute-of-economic , World-health-organisation , Cambridge-judge-business-school

Big relief for import-dependent Indian pharma as Sichuan Airlines resumes cargo services

Big relief for import-dependent Indian pharma as Sichuan Airlines resumes cargo services
India is sourcing almost 70 per cent of drug intermediates, key starting materials and active pharmaceutical ingredients (APIs) -- all essential raw materials needed to manufacture medicines from China
Joe C Mathew | May 12, 2021 | Updated 12:51 IST
Sichuan Airlines resumes cargo services to India
In a major relief to the import-dependent Indian pharmaceutical industry, Chinese state-owned Sichuan Airlines has resumed its cargo services to India. The decision of Sichuan to suspend its services to India due to increasing COVID-19 cases for 15 days from the end of last month had threatened to disrupt the pharmaceutical, medical devices and oxygen concentrator supply chains.

Chengdu , Sichuan , China , India , Gansu , Chinese , Pharmaceuticals-export-promotion-council-of-india-pharmexcil , National-list-of-essential-medicines , Sichuan-airlines , National-list , Essential-medicines

No Covaxin For 18-44 From Tomorrow In Delhi, Limited Stocks Left For 45+

People under the age of 45 won't get shots of Covaxin from tomorrow with limited stocks left for the next four days, the government has said, urging the central government to ensure uninterrupted supplies.

India , Delhi , Narendra-modi , Stocks-left , Tomorrow-in-delhi , Limited-stocks-left-for , Prime-minister-narendra-modi , Corona-virus , Covaxin , Delhi-covid-19-vaccine , Delhi-covid-vaccine , Covaxin-vaccine